Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | Head of Glob Prod Strat & Com | February 18, 2022 | February 23, 2022 |
| Beam Therapeutics Inc.BEAM · Entity 4227 | Director | June 03, 2026 | June 05, 2026 |
| Merck & Co., Inc.MRK · Entity 2807 | EVP, Access, Policy & Comms | August 13, 2026 | August 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date February 18, 2022 · Filed February 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,364 |
Ending reported balance
After 2022-02-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-02-18 · Exercise / conversion · Acquired 1,981 · Balance 8,243 Row 2 · 2022-02-18 · Tax withholding · Disposed 879 · Balance 7,364 |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2024-02-18 | Direct | 12,519 |
Reported balance
After 2022-02-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-02-18 · Exercise / conversion · Disposed 1,981 · Balance 12,519 F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2024-02-18 | Direct | 9,668 |
Reported balance
After 2022-02-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-02-18 · Other · Disposed 2,851 · Balance 9,668 F2: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). |
Filing footnotes · ownership attribution and instrument terms
F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).
F2: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.
Beam Therapeutics Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.55 · Expires 2036-06-03 | Direct | 19,676 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 19,676 · Balance 19,676 F1: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.
Merck & Co., Inc.
Report date August 13, 2026 · Filed August 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,613.127 |
Reported balance
After 2026-08-13 transaction · row 1
1 source rowRow 1 · 2026-08-13 · Sale · Disposed 10,000 · Balance 36,613.127 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2021 Filed Feb 17, 2021 21:58 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 477 | $278.03 | $132,620.31 |
DisclosureSEC source: 0001127602-21-006270 · form4.xml · nonDerivative · entry 4 Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,006 Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:58 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 463 | $278.03 | $128,727.89 |
DisclosureSEC source: 0001127602-21-006270 · form4.xml · nonDerivative · entry 3 Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,483 Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:58 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,622 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006270 · form4.xml · nonDerivative · entry 2 Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,946 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:58 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,534 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006270 · form4.xml · nonDerivative · entry 1 Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 22:41 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 693 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-030492 · form4.xml · derivative · entry 5 Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 693 shares Expires 2020-12-01 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 22:41 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 481 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-030492 · form4.xml · derivative · entry 4 Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 693 Underlying: Common Stock · 481 shares Expires 2020-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 22:41 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 214 | $243.16 | $52,036.24 |
DisclosureSEC source: 0001127602-20-030492 · form4.xml · nonDerivative · entry 3 Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,790 Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 22:41 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 481 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-030492 · form4.xml · nonDerivative · entry 2 Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 22:41 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 348 | $243.16 | $84,619.68 |
DisclosureSEC source: 0001127602-20-030492 · form4.xml · nonDerivative · entry 1 Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,523 Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:34 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 11,450 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005780 · form4.xml · derivative · entry 5 Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,450 Underlying: Common Stock · 11,450 shares Expires 2023-02-12 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:34 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,972 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005780 · form4.xml · derivative · entry 4 Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,308 Underlying: Common Stock · 1,972 shares Expires 2022-02-12 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:34 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,680 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005780 · form4.xml · derivative · entry 3 Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,280 Underlying: Common Stock · 1,680 shares Expires 2022-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:34 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 504 | $331.76 | $167,207.04 |
DisclosureSEC source: 0001127602-20-005780 · form4.xml · nonDerivative · entry 2 Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,871 Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:34 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,680 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005780 · form4.xml · nonDerivative · entry 1 Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 22:59 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 625 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-034176 · form4.xml · derivative · entry 5 Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,174 Underlying: Common Stock · 625 shares Expires 2020-12-01 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 22:59 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 543 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-034176 · form4.xml · derivative · entry 4 Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,799 Underlying: Common Stock · 543 shares Expires 2020-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 22:59 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 160 | $299.81 | $47,969.60 |
DisclosureSEC source: 0001127602-19-034176 · form4.xml · nonDerivative · entry 3 Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,695 Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 22:59 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 543 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-034176 · form4.xml · nonDerivative · entry 2 Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,855 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 22:59 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 231 | $299.81 | $69,256.11 |
DisclosureSEC source: 0001127602-19-034176 · form4.xml · nonDerivative · entry 1 Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,312 Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:11 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 10,960 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006082 · form4.xml · derivative · entry 1 Guindo Chirfi · CIK 0001722753 · EVP Glob. Mkt Acc & Cust Innov 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,960 Underlying: Common Stock · 10,960 shares Expires 2022-02-12 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| December 01, 2018 Filed Dec 5, 2018 01:21 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 566 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-035245 · form4.xml · derivative · entry 5 Guindo Chirfi · CIK 0001722753 · EVP Glob. Mkt Acc & Cust Innov 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,342 Underlying: Common Stock · 566 shares Expires 2020-12-01 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| December 01, 2018 Filed Dec 5, 2018 01:21 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 602 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-035245 · form4.xml · derivative · entry 4 Guindo Chirfi · CIK 0001722753 · EVP Glob. Mkt Acc & Cust Innov 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,908 Underlying: Common Stock · 602 shares Expires 2020-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| December 01, 2018 Filed Dec 5, 2018 01:21 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 178 | $333.72 | $59,402.16 |
DisclosureSEC source: 0001127602-18-035245 · form4.xml · nonDerivative · entry 3 Guindo Chirfi · CIK 0001722753 · EVP Glob. Mkt Acc & Cust Innov 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,543 Read SEC document |
| December 01, 2018 Filed Dec 5, 2018 01:21 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 602 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-035245 · form4.xml · nonDerivative · entry 2 Guindo Chirfi · CIK 0001722753 · EVP Glob. Mkt Acc & Cust Innov 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2018 Filed Dec 5, 2018 01:21 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 231 | $333.72 | $77,089.32 |
DisclosureSEC source: 0001127602-18-035245 · form4.xml · nonDerivative · entry 1 Guindo Chirfi · CIK 0001722753 · EVP Glob. Mkt Acc & Cust Innov 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,119 Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 21:41 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 1,755 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-033939 · form4.xml · derivative · entry 2 Guindo Chirfi · CIK 0001722753 · EVP Glob. Mkt Acc & Cust Innov 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,755 Underlying: Common Stock · 1,755 shares Expires 2020-12-01 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 21:41 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 2,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-033939 · form4.xml · nonDerivative · entry 1 Guindo Chirfi · CIK 0001722753 · EVP Glob. Mkt Acc & Cust Innov 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,350 Read SEC document |
| December 01, 2017 Filed Jan 8, 2018 21:31 UTC Amendment | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 3,510 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-001380 · form4a.xml · derivative · entry 1 Guindo Chirfi · CIK 0001722753 · EVP Glob. Mkt Acc & Cust Innov 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,510 Underlying: Common Stock · 3,510 shares Expires 2020-12-01 F1 · shares: In the original Form 4, the number of Restricted Stock Units acquired was reported at the target payout and should have been reported at the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.